Cargando…
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
HER2 is a promising target for immunotherapeutic interventions with T cell-based approaches since it is amplified and overexpressed in 20–30% of breast cancers. However, several previous studies including ours showed that HER2-overexpressing tumors may escape cytotoxic T lymphocyte-mediated lysis by...
Autores principales: | Inoue, Masayuki, Mimura, Kousaku, Izawa, Shinichiro, Shiraishi, Kensuke, Inoue, Ayako, Shiba, Shugo, Watanabe, Mitsuaki, Maruyama, Takanori, Kawaguchi, Yoshihiko, Inoue, Shingo, Kawasaki, Tomonori, Choudhury, Aniruddha, Katoh, Ryohei, Fujii, Hideki, Kiessling, Rolf, Kono, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494624/ https://www.ncbi.nlm.nih.gov/pubmed/23170258 http://dx.doi.org/10.4161/onci.21056 |
Ejemplares similares
-
Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma
por: Maruyama, T, et al.
Publicado: (2010) -
Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer
por: Nakayama, Yuko, et al.
Publicado: (2019) -
miR-122-5p as a novel biomarker for alpha-fetoprotein-producing gastric cancer
por: Maruyama, Suguru, et al.
Publicado: (2018) -
Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting
por: Kono, Koji, et al.
Publicado: (2013) -
Radiotherapy-Induced Anti-Tumor Immunity Contributes to the Therapeutic Efficacy of Irradiation and Can Be Augmented by CTLA-4 Blockade in a Mouse Model
por: Yoshimoto, Yuya, et al.
Publicado: (2014)